Robert F. Poirier, Jr. MD, on the Approval of Lefamulin for CABP
December 13th 2019In August, the FDA approved lefamulin (Xenleta) for the treatment of CABP after results from 2 phase 3 studies showed that the novel antibiotic was noninferior to existing treatment options.
Read More
Two More Agents Bolster the Arsenal Against Gram-Negative Resistance
December 12th 2019As the antibiotic pipeline produces new therapies, clinicians must understand each agent’s specific role in manage­ment of patients infected by multidrug-resistant pathogens.
Read More
An Unknown Contagious Rash: Case Report and Literature Review of Norwegian Crusted Scabies
A patient with HIV and skin lesions should trigger a broad differential.
Read More
Alternative Antiretroviral Medication Delivery Systems Emerge to Treat, Prevent HIV Infection
Novel modes of delivery are imperative to improve HIV suppression and prevent transmission.
Read More
Get Off the SOFA! Introducing the Quick Pitt Bacteremia Score
The quick Pitt Bacteremia Score offers accuracy comparable to the original version's across multiple infections, and maintains ease of use.
Read More
Differences in C difficile Diagnostics Blunt the Benefits of Bezlotoxumab
December 3rd 2019Bezlotoxumab, a human monoclonal anti­body directed against Clostridioides diffi­cile toxin B, is currently indicated for the prevention of recurrent C diffi­cile infection
Read More
ACX-362E a Promising Potential Treatment for C difficile, First-in-Human Phase 1 Trial Demonstrates
October 2nd 2019Investigators observed no moderate, severe, cumulative, or dose-limiting adverse events leading to discontinuation, and ACX-362E was generally well-tolerated at all dose levels.
Read More